GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines

 GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines

Shots:

  • CureVac to receive $90.14M up front, $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have exclusive rights in all countries except Germany, Austria and Switzerland
  • Additionally, GSK will support the manufacture of ~100M doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021
  • The development program will begin imminently, with the target of introducing the vaccine in 2022, subject to regulatory approval

Click here ­to­ read full press release/ article | Ref: GSK | Image: The Guardian Nigeria

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post